Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01692626 · ClinicalTrials.gov registry record · Phase 2
1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX
A Phase 2 study, sponsored by West Virginia University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT01692626 is a Phase 2 study that was terminated before completion, run by West Virginia University. The registered enrollment target is 13 participants.
The verdict
NCT01692626, a Phase 2 study, was terminated before completion, sponsored by West Virginia University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
When cancer patients are treated with the drug cetuximab they very often develop a rash. Usually it appears on their face and back and other parts of the body. The rash looks like acne and is treated with skin creams or antibiotics most of the time. The rash can become very painful and cause patients to stop using cetuximab to treat their cancer, even if cetuximab was helping fight their cancer. Cetuximab is known to be a good drug to help treat cancer. This study will help us learn about the rash cetuximab causes so hopefully future patients can finish taking cetuximab for their cancer. In this study the investigators will use a cream called pimecrolimus (Elidel) to see if it will help prevent the rash or keep the rash from getting worse. The investigators also want to see how the rash affects patients and their quality of life. Participants will be in this study for about four weeks if their rash does not get worse. They will need to apply the study cream and placebo two times daily and answer quality of life questionnaires during this study. Participants will also be seen by a dermatologist and have pictures taken of their rash.
Interventions
- DRUG Placebo
- DRUG Pimecrolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2012-02 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01692626
The ClinicalTrials.gov registry entry for NCT01692626 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is West Virginia University, which has 122 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01692626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01692626 about?
NCT01692626 is a clinical study titled "1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX". When cancer patients are treated with the drug cetuximab they very often develop a rash. Usually it appears on their face and back and other parts of the body. The rash looks like acne and is treated with skin creams or antibiotics most of the time. The rash can become very painful and cause patient...
What is the current status of trial NCT01692626?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2012-02. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01692626?
The interventions under investigation include: Placebo (DRUG), Pimecrolimus (DRUG).
Who is sponsoring clinical trial NCT01692626?
This trial is sponsored by West Virginia University, which has 122 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.